- The document describes a study that constructed a disease network using clinical data from claims records.
- Researchers extracted disease-disease pairs from patient records to represent relationships between previous and later diagnosed diseases.
- The resulting disease network had 775 nodes and over 4,000 edges, with edges colored to represent sex-dominant relationships.
- Analysis found the network followed a scale-free structure and that degree of older patients and diseases were higher. Communities were identified.
- The disease network was compared to a gene-disease network, finding some novel relationships not previously identified.
Is the increasing availability of automated image analysis a possibility to strengthen the application of diffusion-MRI as a biometric parameter, and to enhance the future of image biobanks? Or is this evolution threatening the position of radiologists as medical doctors. Is a redefinition of radiologist as computer technicians inevitable?
Day 2 Big Data panel at the NIH BD2K All Hands 2016 meetingWarren Kibbe
Big data in oncology and implications for open data, open science, rapid innovation, data reuse, reproducibility and data sharing. Cancer Moonshot, Precisions Medicine Initiative (PMI), the Genomic Data Commons, NCI Cloud Pilots, NCI-DOE Pilots, and the Cancer Research Data Ecosystem.
SILS 2015 - Connecting Precision Medicine to Precision Wellness Sherbrooke Innopole
By: Joel Dudley, Mount Sinai School of Medicine
At Sherbrooke International Life Sciences Summit - 2nd edition | September 28/29/30 2015
www.sils-sherbrooke.com
Is the increasing availability of automated image analysis a possibility to strengthen the application of diffusion-MRI as a biometric parameter, and to enhance the future of image biobanks? Or is this evolution threatening the position of radiologists as medical doctors. Is a redefinition of radiologist as computer technicians inevitable?
Day 2 Big Data panel at the NIH BD2K All Hands 2016 meetingWarren Kibbe
Big data in oncology and implications for open data, open science, rapid innovation, data reuse, reproducibility and data sharing. Cancer Moonshot, Precisions Medicine Initiative (PMI), the Genomic Data Commons, NCI Cloud Pilots, NCI-DOE Pilots, and the Cancer Research Data Ecosystem.
SILS 2015 - Connecting Precision Medicine to Precision Wellness Sherbrooke Innopole
By: Joel Dudley, Mount Sinai School of Medicine
At Sherbrooke International Life Sciences Summit - 2nd edition | September 28/29/30 2015
www.sils-sherbrooke.com
National Cancer Data Ecosystem and Data SharingWarren Kibbe
Grand Rounds at the Siteman Cancer Center at Washington University. Highlighting the Genomic Data Commons and the National Cancer Data Ecosystem defined by the Cancer Moonshot Blue Ribbon Panel
FDA NGS and Big Data Conference September 2014Warren Kibbe
Presentation for the FDA NGS and Big Data Conference September 2014 held on the NIH campus. NCI initiatives, including Cancer Genomics Data Commons, NCI Cloud Pilots, big data issues for cancer
Human Disease Ontology Project presented at ISB's Biocurator meeting April 2014Lynn Schriml
The Human Disease Ontology (DO), organized as a directed acyclic graph, represents a knowledge base of inherited, environmental, infectious diseases (http://www.disease-ontology.org). DO's textual definition model incorporates a semi-structured format describing the disease etiology built to capture the complex nature of human disease etiology within a is_a hierarchy. DO includes disease concepts for cancer, metabolic disease, infectious disease, mental disorders, genetic disease and syndromes. DO contains disease definitions, external references to resources including ICD, NCI-metathesaurus, SNOMED, MeSH and OMIM and extended relationships that conform to OBO guidelines. DO provides a central ‘switchboard’ for connecting resources, datasets, and computational tools that include disease terms or relationships.
Disease Ontology: Improvements for Clinical Care and Research ApplicationsLynn Schriml
Human Disease Ontology, www.disease-ontology.org
Standardized descriptions of human disease that improve capture and communication of health-related data across biomedical resources.
Presentation by our Keynote Speaker, Leslie J. Kohman, MD at our Cancer Mission 2020 28th Congressional District Summit in Buffalo, NY. Dr. Kohman is the Professor of Surgery Medical Director at Upstate Cancer Center in Syracuse, NY.
OMIM Integration in Human Disease OntologyLynn Schriml
Genetic diseases in the Human Disease Ontology are cross mapped to OMIM (www.omim.org). Here we present the process on data integration and management for coordinating data updates across resources.
Patient-Organized Genomic Research StudiesMelanie Swan
DIYgenomics has developed a methodology for the conduct of patient-organized genomic research studies, obtaining outcomes by linking genomic data to phenotypic data and intervention. The general hypothesis is that individuals with one or more polymorphisms in the main variants associated with conditions may be more likely to have baseline out-of-bounds phenotypic biomarker levels, and could benefit the most from targeted intervention.
DIYgenomics: An Open Platform for Democratizing the GenomeMelanie Swan
Redesigning biology may be man's ultimate artistic and scientific exploit. The first steps are reading and writing genetic data with DNA sequencing and synthetic biology. Already human genome sequencing costs have declined such that individuals worldwide are accessing their own genomic data, and can explore it through open-source science communities such as DIYgenomics.
Crowdsourcing applied to knowledge management in translational research: the ...SC CTSI at USC and CHLA
Date: November 8th, 2018
Speaker: Andrew Su, PhD, Professor, Department of Integrative, Structural and Computational Biology, The Scripps Research Institute
Overview: Crowdsourcing involves the engagement of large communities of individuals to collaboratively accomplish tasks at massive scale. These tasks could be online or offline, paid or for free. But how can crowdsourcing science help your research? This webinar will describe two crowdsourcing projects for translational research, both of which aim to better organize biomedical information so that it can be more easily accessed, integrated, and queried:
First, the goal of the Gene Wiki project is to create a community-maintained knowledge base of all relationships between biological entities, including genes, diseases, drugs, pathways, and variants. This project draws on the collective efforts of informatics researchers from a wide range of disciplines, including bioinformatics, cheminformatics, and medical informatics.
Second, the Mark2Cure project partners with the citizen scientist community to extract structured content from biomedical abstracts with an emphasis on rare disease. Although citizen scientists do not have any specialized expertise, after receiving proper training, Mark2Cure has shown that in aggregate they perform bio-curation at an accuracy comparable to professional scientists.
Lessons from COVID-19: How Are Data Science and AI Changing Future Biomedical...Jake Chen
: COVID-19 has profoundly impacted all our lives. Not all such impacts in science are negative. For example, how we adapt to online learning, remote mentorship, and online teamwork may become new “norms” of future scientific collaborations, breaking down institutional boundaries to communication. The COVID-19 pandemic has united the scientific community more than ever, through more than 3600 clinical trials, 60,000 peer-reviewed publications, 80,000 SARS-CoV-2 genome sequences, 100,000 COVID-19 open software tools, and a global community of scientists, with which all of us are working hard to find epidemiological patterns, diagnosis, therapeutics, and vaccines in a “War Against COVID-19”. In this talk, I will define and characterize data-driven medicine primarily through my personal journey in the past ten months, having witnessed the rapid “weaponizing of data science tools” in our community’s fight against COVID-19 (including ours, at http://covid19.ubrite.org/). I will review up-to-date COVID-19 literature, especially those related to how biomedical informatics, data science, and artificial intelligence have been applied in accelerating COVID-19 breakthrough discoveries, from basic research to clinical practice. I will end by sharing my thoughts on how the future of medicine in cancer and other translational areas can benefit from the proactive incorporation of new “data science engines.”
National Cancer Data Ecosystem and Data SharingWarren Kibbe
Grand Rounds at the Siteman Cancer Center at Washington University. Highlighting the Genomic Data Commons and the National Cancer Data Ecosystem defined by the Cancer Moonshot Blue Ribbon Panel
FDA NGS and Big Data Conference September 2014Warren Kibbe
Presentation for the FDA NGS and Big Data Conference September 2014 held on the NIH campus. NCI initiatives, including Cancer Genomics Data Commons, NCI Cloud Pilots, big data issues for cancer
Human Disease Ontology Project presented at ISB's Biocurator meeting April 2014Lynn Schriml
The Human Disease Ontology (DO), organized as a directed acyclic graph, represents a knowledge base of inherited, environmental, infectious diseases (http://www.disease-ontology.org). DO's textual definition model incorporates a semi-structured format describing the disease etiology built to capture the complex nature of human disease etiology within a is_a hierarchy. DO includes disease concepts for cancer, metabolic disease, infectious disease, mental disorders, genetic disease and syndromes. DO contains disease definitions, external references to resources including ICD, NCI-metathesaurus, SNOMED, MeSH and OMIM and extended relationships that conform to OBO guidelines. DO provides a central ‘switchboard’ for connecting resources, datasets, and computational tools that include disease terms or relationships.
Disease Ontology: Improvements for Clinical Care and Research ApplicationsLynn Schriml
Human Disease Ontology, www.disease-ontology.org
Standardized descriptions of human disease that improve capture and communication of health-related data across biomedical resources.
Presentation by our Keynote Speaker, Leslie J. Kohman, MD at our Cancer Mission 2020 28th Congressional District Summit in Buffalo, NY. Dr. Kohman is the Professor of Surgery Medical Director at Upstate Cancer Center in Syracuse, NY.
OMIM Integration in Human Disease OntologyLynn Schriml
Genetic diseases in the Human Disease Ontology are cross mapped to OMIM (www.omim.org). Here we present the process on data integration and management for coordinating data updates across resources.
Patient-Organized Genomic Research StudiesMelanie Swan
DIYgenomics has developed a methodology for the conduct of patient-organized genomic research studies, obtaining outcomes by linking genomic data to phenotypic data and intervention. The general hypothesis is that individuals with one or more polymorphisms in the main variants associated with conditions may be more likely to have baseline out-of-bounds phenotypic biomarker levels, and could benefit the most from targeted intervention.
DIYgenomics: An Open Platform for Democratizing the GenomeMelanie Swan
Redesigning biology may be man's ultimate artistic and scientific exploit. The first steps are reading and writing genetic data with DNA sequencing and synthetic biology. Already human genome sequencing costs have declined such that individuals worldwide are accessing their own genomic data, and can explore it through open-source science communities such as DIYgenomics.
Crowdsourcing applied to knowledge management in translational research: the ...SC CTSI at USC and CHLA
Date: November 8th, 2018
Speaker: Andrew Su, PhD, Professor, Department of Integrative, Structural and Computational Biology, The Scripps Research Institute
Overview: Crowdsourcing involves the engagement of large communities of individuals to collaboratively accomplish tasks at massive scale. These tasks could be online or offline, paid or for free. But how can crowdsourcing science help your research? This webinar will describe two crowdsourcing projects for translational research, both of which aim to better organize biomedical information so that it can be more easily accessed, integrated, and queried:
First, the goal of the Gene Wiki project is to create a community-maintained knowledge base of all relationships between biological entities, including genes, diseases, drugs, pathways, and variants. This project draws on the collective efforts of informatics researchers from a wide range of disciplines, including bioinformatics, cheminformatics, and medical informatics.
Second, the Mark2Cure project partners with the citizen scientist community to extract structured content from biomedical abstracts with an emphasis on rare disease. Although citizen scientists do not have any specialized expertise, after receiving proper training, Mark2Cure has shown that in aggregate they perform bio-curation at an accuracy comparable to professional scientists.
Lessons from COVID-19: How Are Data Science and AI Changing Future Biomedical...Jake Chen
: COVID-19 has profoundly impacted all our lives. Not all such impacts in science are negative. For example, how we adapt to online learning, remote mentorship, and online teamwork may become new “norms” of future scientific collaborations, breaking down institutional boundaries to communication. The COVID-19 pandemic has united the scientific community more than ever, through more than 3600 clinical trials, 60,000 peer-reviewed publications, 80,000 SARS-CoV-2 genome sequences, 100,000 COVID-19 open software tools, and a global community of scientists, with which all of us are working hard to find epidemiological patterns, diagnosis, therapeutics, and vaccines in a “War Against COVID-19”. In this talk, I will define and characterize data-driven medicine primarily through my personal journey in the past ten months, having witnessed the rapid “weaponizing of data science tools” in our community’s fight against COVID-19 (including ours, at http://covid19.ubrite.org/). I will review up-to-date COVID-19 literature, especially those related to how biomedical informatics, data science, and artificial intelligence have been applied in accelerating COVID-19 breakthrough discoveries, from basic research to clinical practice. I will end by sharing my thoughts on how the future of medicine in cancer and other translational areas can benefit from the proactive incorporation of new “data science engines.”
Genomics, Cellular Networks, Preventive Medicine, and SocietyLarry Smarr
09.12.11
Invited Talk
Guest Lecture to UCSD Medical and Pharmaceutical Students
Genetics in Medicine Course
Amphitheater of the Pharmaceutical Sciences Bldg
Title: Genomics, Cellular Networks, Preventive Medicine, and Society
La Jolla, CA
Twenty Years of Whole Slide Imaging - the Coming Phase ChangeJoel Saltz
I surveyed the development of Digital Pathology methodology beginning with the 1997 virtual microscope prototype at Hopkins (PMC2233368) to current tools, methods and algorithms designed to display, analyze and classify whole slide imaging data. I will describe the capabilities of current methods, describe how these methods are likely to evolve and how they will be likely to impact Pathology research and practice.
Twenty Years of Whole Slide Imaging - the Coming Phase ChangeJoel Saltz
Presentation at Pathology Visions 2017 - https://digitalpathologyassociation.org/2017-pathology-visions-agenda
I will survey the development of Digital Pathology methodology beginning with the 1997 virtual microscope prototype at Hopkins (PMC2233368) to current tools, methods and algorithms designed to display, analyze and classify whole slide imaging data. I will describe the capabilities of current methods, describe how these methods are likely to evolve and how they will be likely to impact Pathology research and practice.
American Association for Cancer Research Annual Meeting 2022
Analysis of images of routinely acquired tissue specimens promise to provide biomarkers that can be used to predict disease outcome and steer treatment, improve diagnostic reproducibility, and reveal new insights to further advance current human understanding of disease. The advent of AI and ubiquitous high-end computing are making it possible to carry out accurate whole slide image morphological and molecular tissue analyses at cellular and subcellular resolutions. AI methods are can enable exploration and discovery of novel diagnostic biomarkers grounded in prognostically predictive spatial and molecular patterns as well as quantitative assessments of predictive value and reproducibility of traditional morphological patterns employed in anatomic pathology. AI methods may be adapted to help steer treatment through integrative analysis of clinical information along with Pathology, Radiology and molecular data.
Morphologomics - Challenges for Surgical Pathology in the Genomic Age by Dr. ...Cirdan
This presentation introduces and discussesthe concept of ‘morphologomics’ that is omics approaches critically reimagined and reappraised from the viewpoint of classic morphology.
It was delivered by Dr. Anthony Gill at the Pathology Horizons 2017 conference in Cairns, Australia.
introduce and discuss the concept of ‘morphologomics’ that is omics approaches critically reimagined and reappraised from the viewpoint of classic morphology.
Genomics in Society: Genomics, Cellular Networks, Preventive Medicine, and So...Larry Smarr
10.10.06
Guest Lecture
UCSD Medical and Pharmaceutical Students Foundations of Human Biology--Lecture #41
Title: Genomics in Society: Genomics, Cellular Networks, Preventive Medicine, and Society
La Jolla, CA
TCGC The Clinical Genome Conference 2015Nicole Proulx
Bio-IT World and Cambridge Healthtech Institute are again proud to host the Fourth Annual TCGC: The Clinical Genome Conference, inviting stakeholders impacting clinical genomics to share new findings and solutions for advancing the applications of clinical genome medicine.
Advancing Innovation and Convergence in Cancer Research: US Federal Cancer Mo...Jerry Lee
Special Seminar at the 8th Taiwan Biosignatures Workshop to share overall work of NCI's Center for Strategic Scientific Initiatives since 2003 as well as CSSI's influence on select projects initiated by the 2016 WH Cancer Moonshot Task Force that include Applied Proteogenomics Organizational Learning and Outcomes (APOLLO) network, International Cancer Proteogenome Consortium, and the Blood Profiling Atlas in Cancer (BloodPAC) commons.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Basavarajeeyam is an important text for ayurvedic physician belonging to andhra pradehs. It is a popular compendium in various parts of our country as well as in andhra pradesh. The content of the text was presented in sanskrit and telugu language (Bilingual). One of the most famous book in ayurvedic pharmaceutics and therapeutics. This book contains 25 chapters called as prakaranas. Many rasaoushadis were explained, pioneer of dhatu druti, nadi pareeksha, mutra pareeksha etc. Belongs to the period of 15-16 century. New diseases like upadamsha, phiranga rogas are explained.
CDSCO and Phamacovigilance {Regulatory body in India}NEHA GUPTA
The Central Drugs Standard Control Organization (CDSCO) is India's national regulatory body for pharmaceuticals and medical devices. Operating under the Directorate General of Health Services, Ministry of Health & Family Welfare, Government of India, the CDSCO is responsible for approving new drugs, conducting clinical trials, setting standards for drugs, controlling the quality of imported drugs, and coordinating the activities of State Drug Control Organizations by providing expert advice.
Pharmacovigilance, on the other hand, is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. The primary aim of pharmacovigilance is to ensure the safety and efficacy of medicines, thereby protecting public health.
In India, pharmacovigilance activities are monitored by the Pharmacovigilance Programme of India (PvPI), which works closely with CDSCO to collect, analyze, and act upon data regarding adverse drug reactions (ADRs). Together, they play a critical role in ensuring that the benefits of drugs outweigh their risks, maintaining high standards of patient safety, and promoting the rational use of medicines.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
The Gram stain is a fundamental technique in microbiology used to classify bacteria based on their cell wall structure. It provides a quick and simple method to distinguish between Gram-positive and Gram-negative bacteria, which have different susceptibilities to antibiotics
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Evaluation of antidepressant activity of clitoris ternatea in animals
Network medicine
1. 대한생물정신의학회 2018 춘계 학술대회
Construction and Interpretation of
Disease Network using Clinical Data
차의과학대학교 의학전문대학원 정보의학교실
한현욱 (M.D, Ph.D)
stepano7@gmail.com
2. C.V
Position
Head Professor, Dept. of Biomedical Informatics, CHA University
Head, Healthcare Big Data Laboratory, CHA University (CHABI)
Scientific Program Committee Member, Translational Bioinformatics Conference
Instructor, GDA and CPBMI, KOSMI
Advisor Medibloc, Syntecabio, and MISOinfo
Education
CPBMI, Certified Physician in BioMedical Informatics, KOSMI
Ph.D, Biomedical Informatics, Graduate School of Medicine, CHA University
M.D, Gradate School of Medicine, CHA University
M.S, Dept. of Electrical & Computer Engineering, Seoul National University
B.S, Dept. of Electrical & Computer Engineering, Hanyang University
Work
Research Assistant Professor, Dept. of Biomedical Informatics, Ajou University
Clinical Assistant Professor, Dept. of Preventive Medicine, CHA University
Research Scientist, Systems Biomedical Informatics Research Center, SNU
R&D Engineer, LG Electronics R&D Campus
7. Biological Network
Protein Interaction
Network
Network biology
Network Medicine
Regulatory
Network
Metabolic
Network
Cell Signaling
Network
Perturbation
Sensitivity Network
Social Network
Disease Network
Drug Target
Network
8. Network Science
20C Network (Complex System) Science
Opposing to Reductionism
Barabasi et al.
Network Topologies
Random Network Scale-free Network
9. Characterization of Real Network
P(k) ∝ λ-γ (2 < γ < 3)
Hub node vs. peripheral node
Evolution
Small world phenomenon
Six degrees of separation
The 80/20 rule
Rich get richer
Achilles' Heel
Scale-free network
Network growth
Preferential attachment
Social Network
Internet Network
Biological Network
log-log
10. Previous Researches of Biological Network
PPI is scale-free
(Barabasi, 2000)
Centrality & Lethality
rule (Jeong, 2001)
Hubs evolve slowly
(Fraser, 2002)
Disease : clustering,
tissue specificity &
Periphery (Goh, 2007)
Drug target : similar
with disease genes
(Yildirim, 2007)
14. Previous Disease Network
Human Symptoms – Disease Network (Barabasi et al. 2014,
Nature Communication) : EMR Base
Disease A – Symptom 1
Disease B – Symptom 1
Disease A – Symptom 1 -- Disease B
Disease A- Disease B
15. Previous Disease Network
Disease Comorbidity Network (Yang Chen, 2015, AMIA)
상병명 : Disease A ,Disease B
Disease A- Disease B
16. Motivation
Definition of Disease (Wiki)
질병(疾病)이란 유기체의 신체적 기능이 비정상적으로 된 상태를
일컫는다.
인간에게 있어서 질병이란 넓은 의미에서는 극도의 고통을
비롯해 스트레스, 사회적인 문제, 신체기관의 기능
장애와 죽음에까지를 포괄한다.
질병이란 개인만에 한정되는 것이 아니어서 사회적으로 큰
맥락에서 이해되기도 한다.
더 넓게는 사고나 장애, 증후군, 감염, 행동 장애 등을 모두 나타낼
수 있다.
질병의 종류에는 약 30000가지 정도가 있다고 한다.
17. Motivation
Genetic Disease Vs. Non-Genetic Disease
Many diseases have no genetic basis at all. Usually a physical
injury such as a bone fracture is not caused by genetics when it
is caused by something else. (Of course, there could still be an
underlying genetic cause of weak bones or osteoporosis that
really caused the fracture.) Similarly, a virus or bacterial
infection is caused by an external microbe
예방의학교과서
유전체로 설명될 수 있는 질환은 20~30% 정도로 알려져 있음
Most diseases are non-genetic
27. NHIS Cohort Data
A B C
A B, BC, AC
Sex, Age, Direction, Weight, Duration
28. Method
• Assumption
• we extracted all combinations of disease-disease pairs
from each patient’s transition based on the assumption
that “previous incidence would become a cause (or act as a
risk factor) of later incidence” .
• Step 1. 3 types of event sequence:
• Incidence sequence
• Ex: A B C D
• Step 2. Extracting disease-disease pairs:
• Disease-disease pairs : (A B), (A C), (A D), (B C),
(B D), (C D)
• Step 3. Record the frequency of each disease-
disease pair
29. Method
Statistical analysis and constructions of the human disease directed network. A: databases of the sample cohort data. B: 5 variables from
the sample cohort data and the disease codes selection process. C: Extracting the disease-disease relationships and the frequency records
in the Dn x Dm table
31. Result
Network Construction
775 node
4,100 edge
Edge color - Blue : male-dominant – 329
Red : female-dominant – 1,868
Green: not sex-dominant – 3,539
32. Results
0-20 20-40
40-60>60
Sex and Age are important factors in determining the structural dynamics of
disease networks.
Network Construction
33. Results
Degree Analysis
• DPN is a typical scale-free network
• The positive correlation between
the in- and out-degrees of diagnoses
34. Results
• ICD-10 categories are determined according to in- and out-degrees of diagnoses
• Old age has high in- and out-degree
Degree Analysis
35. Results
• Community detection in the DPN formed
88 clusters.
• Six giant cluster had distinct properties
(Sex, Aage, ICD-10 categories)
Community Analysis
37. Results
DPN vs. gene-disease network (GDN) of Cancer
29 disease categories (DPN : 27 pair, GDN : 261 pair)
14 of 27 links In the DPN overlapped with the links in the GDN
What is the 13 links?
Example of 13 links Evidence
“Colon cancer” (C18) and
“Prostate cancer” (C61)
Fitzgibbons, R. J. Jr., Lynch, H. T. &
Salerno, G. M. Hereditary colon
cancer syndromes
“Bladder cancer” (C67) and “Lung
cancer” (C34)
Kantor, A. F. & McLaughlin, J. K.
Second cancer following cancer of
the urinary system in Connecticut,
1935–82. Natl Cancer Inst Monogr
68, 149–159 (1985)
38. Results
Practical Usability
• Supporting Network visualization according to Sex, Age, Disease-pair, Duration,
Relative Risk and Directionality
40. Conclusion
We built a directional weighted network with duration information using
claim data
We showed that our network had both in-degree and out-degree
distributions following a power law (Scale-free Network)
Older patients are more likely to have been exposed to various diseases
Disease Network is grouped by gender, age, and ICD-10 categories.
Our network presented clinically meaningful connectivity and also identified
connectivity that were not previously found in the gene-disease network
(the macroscopic level, such as the metastasis of cancer)
The network presented here may potentially serve as a predictive tool for
the diagnosis and treatment of diseases
이를 위해 먼저 헬스케어 데이터에는 어떤것이 있는지 간단히 살펴보고
이슈가 되는 몇가지 사항에 대하 정리할 필요가 있습니다.
또 하나 중요한 헬스케어 데이터가 바로 연구데이터 입니다 .
최근 대학 병원에서는 임상시험 센터를 유행처럼 만들고 있습니다.
이를 통해, 병원의 수익을 올릴 뿐만 아니라, 신약 혹은 새로운 치료법에 관한 임상적 관찰된 데이터가 쏟아지고 있어…
최근에는 이런 데이터를 전문적으로 관리 및 분석하기 위한 IT인프라가 구축되고 있습니다.
대표적인 예가 세브란스의 e-CASE라는 서비스인데, 이런 서비스를 활용해 기존의 병원정보시스템의 데이터와 임상시험 데이터를 연계한
빅데이터 분석이 이루어 지고 있습니다.
분자생물학의 발전으로 인해 현재, 웻 랩에서 생상되는 다양한 분자생물학 실험 데이터가 생산되고 있습니다.
최근에는 하이스루풋 분자생물학 실험 데이터가 쏟아지고 있어 연구실 차원의 분자생물학 데이터가 넘쳐나고 있고 이를 관리하기 위한 다양한 림스가 등장하고 있습니다.
한편, 전세계적으로 다양한 생물학적 데이터베이스가 무료로 개방되고 있는데
이를 분석하기 위한 DAVI와 같은 생명정보분석 시스템도 계속해서 등장하고 있는중 입니다.
웨어러블과 스마트기기의 발전으로 인해 과거에는 존재하지 않았던 헬스케어 데이터가
이제는 의료기관 밖에서도 생산되고 있습니다.
여기서 문제점은 디지털 헬스케어 업체마다 데이터 형태가 너무 다양해 표준화 시키기 어렵다는게 문제입니다.
최근에는 모바일 헬스케어 표준안에 관한 다양한 연구가 본격적으로 진행중에 있어 미래에는 데이터 개방으로 인해 다양한 PGHD가 생산되고
활용될것으로 기대됩니다.
현재, 이런 데이터를 활용해 독감예측 을 위한 모바일닥터, 벨트형 비만관리앱 웰트, 당뇨관리 앱 휴레이 포지티브와 같은
디지털 헬스케어 기업이 만들어지고 있습니다.
매우 혼란스러울 겁니다. 왜냐하면 일본과 한국의 표준화 방법이 다르기 때문입니다.
따라서 하루 빨리 표준화를 이루기 위해 노력해야 합니다.
데이터에 대한 신뢰성, 무결성, 보안성 그리고 투명성을 확보해야 합니다.
그리고 데이터 제공자에게 적절한 보상이 이루어져야 하며 데이터에 대한 표준화 이슈도 함께 해결해야 합니다.